A case of organizing pneumonia in rearranged during transfection fusion‐positive lung adenocarcinoma treated with selpercatinib by Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima

Subjects: Get full text

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review by Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu

Subjects: Get full text

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system by Qiong Jie, Yuanyuan Li, Li Jing, Jinjin Chen, Yang Li

Subjects: Get full text

ESMO Updates the Guidelines for the Diagnosis of RET-Altered Cancer to Herald a New Era in Targeted Therapy by Alfredo Addeo, Frank Stenner

Subjects: Get full text

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database by Jiancheng Qian, Shuohan Zhang, Cheng Jiang

Subjects: “…Selpercatinib…”
Get full text

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report by Daniela Scattolin, Daniela Scattolin, Elena Scagliori, Antonio Scapinello, Alberto Fantin, Valentina Guarneri, Valentina Guarneri, Giulia Pasello, Giulia Pasello

Subjects: Get full text

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma by Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet

Subjects: Get full text

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Re... by Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William, William Nassib William

Subjects: Get full text

Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis by Dongmei Huang, Jinming Zhang, Xiangqian Zheng, Ming Gao

Subjects: Get full text

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) by Rachel E. Reingold, MD, Rose Parisi, MD, MBA, Guilherme Harada, MD, Andrea P. Moy, MD, George Dranitsaris, PhD, Jasmine H. Francis, MD, Julia Canestraro, OD, FAAO, Julia A. Lester, MPH, Lauren A. Kaplanis, RN, Dazhi Liu, PharmD, BCOP, Mario E. Lacouture, MD, Alexander Drilon, MD

Subjects: “…Selpercatinib…”
Get full text

Current Guidelines for Management of Medullary Thyroid Carcinoma by Mijin Kim, Bo Hyun Kim

Subjects: Get full text

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case by Raffaella Pagliaro, Raffaella Pagliaro, Paola Maria Medusa, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Luigi Aronne, Susan F. M. Campbell, Susan F. M. Campbell, Fabio Perrotta, Fabio Perrotta, Andrea Bianco, Andrea Bianco

Subjects: Get full text

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC by Elisa De Carlo, Elisa Bertoli, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz

Subjects: Get full text

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report by Paolo D. d'Arienzo, MD, MRCP, Niamh Cunningham, MBBS, BSc, MRCP, Hazel O’Sullivan, MBBchBAO, MRCPI, Charlotte Grieco, MBBS, MRCP, Virjen Patel, MbChB, BSc, FRCR, Sanjay Popat, PhD, FRCP

Subjects: “…Selpercatinib…”
Get full text

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer by Tomoya Yokota

Subjects: “…selpercatinib…”
Get full text

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration by Kazuhisa Nakashima, Yuki Mitarai, Seiko Tanaka, Mika Nakao, Takae Okuno, Tamio Okimoto, Ryo Tanabe, Takashi Yanagawa, Yukari Tsubata, Takeshi Isobe

Subjects: Get full text

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC by Badi El Osta, MD, Suresh S. Ramalingam, MD, FACP, FASCO

Subjects: Get full text

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020 by Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD

Subjects: Get full text

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer by Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno

Subjects: Get full text

Biomarker testing in non-small cell lung carcinoma – More is better: A case series by Ullas Batra, Mansi Sharma, Shrinidhi Nathany, Satyajeet Soni, Abhishek Bansal, Parveen Jain, Anurag Mehta

Subjects: Get full text